A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC)
tablets of canagliflozin and metformin immediate release (IR) in comparison with the
individual components of the FDC tablets (canagliflozin and metformin IR).